HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization
Affiliations: Department of Pharmacology, Kwandong University College of Medicine, Gangneung 210-701, Republic of Korea, KIST Gangneung Institute, Ga-17 Block, Gangneung Techno Valley, Daejeon-dong, Gangneung, Gangwon-do 210-340, Republic of Korea, Department of Pharmacology, Kwandong University College of Medicine, 522 Naegok-dong, Gangneung-si, Gangwon-do 210-701, Republic of Korea
- Published online on: December 17, 2010 https://doi.org/10.3892/ijo.2010.879
- Pages: 807-812
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...
This article is mentioned in:
Although histone deacetylase (HDAC) inhibitors are emerging as a promising class of cancer chemotherapeutic agents, their effects on multidrug resistance (MDR) are poorly understood. In this study, we investigated whether HDAC inhibitors overcome MDR phenotype. HDAC inhibitors suppress the growth of both MDR positive cancer cells KBV20C and its parental cells KB with similar potencies. In parallel, histone acetylation and p21WAF1 expression by the HDAC inhibitors were similarly increased in both cell types, indicating that these HDAC inhibitors are poor substrates of ABC drug transporters and effective in MDR cancer cells. In addition, multidrug resistance protein 2 (MRP2) expression is selectively attenuated by HDAC inhibitors, especially SAHA and TSA, in KBV20C cells, whereas MDR1 and BCRP expressions are not affected. This downregulation of MRP2 contributes to increase in paclitaxel-induced G2/M arrest and apoptosis, which might be due to intracellular accumulation of paclitaxel. Collectively, our data provide a molecular rationale for the application of HDAC inhibitors to overcome MDR in cancer cells.